Barclays Maintains Equal-Weight on PTC Therapeutics, Lowers Price Target to $26
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang has maintained an Equal-Weight rating on PTC Therapeutics (NASDAQ:PTCT) but lowered the price target from $44 to $26.
September 18, 2023 | 2:14 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Barclays has maintained an Equal-Weight rating on PTC Therapeutics but lowered the price target from $44 to $26.
The lowering of the price target by Barclays indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on PTC Therapeutics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100